recombinant neohirudin

Recombinant neohirudin is a direct thrombin inhibitor developed by the Institute of Radiation and Radiation Medicine at the Academy of Military Medical Sciences in China. It is a recombinant polypeptide expressed in yeast (*Pichia pastoris*), derived from hirudin, the potent anticoagulant naturally found in the saliva of medicinal leeches (*Hirudo medicinalis*). Neohirudin acts by binding with high specificity and affinity to thrombin, effectively blocking its enzymatic activity and preventing the conversion of fibrinogen into fibrin. This mechanism inhibits the formation of blood clots, making it a candidate for the prevention and treatment of deep vein thrombosis (DVT). Clinical development has included Phase I studies in healthy subjects to evaluate safety, tolerability, and pharmacokinetics.

Other names

Xinzhisu新蛭素